Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma
Paul Chapman, MD
Advertisement
Articles by Paul Chapman, MD
Dr. Chapman from Memorial Sloan-Kettering Cancer Center on Vemurafenib Combination Therapies
Dr. Chapman From Memorial Sloan-Kettering Cancer Center Describes Recent Melanoma Advances
Dr. Chapman From Memorial Sloan-Kettering Describes the Vemurafenib Clinical Trial
Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib
Advertisement
Latest Updated Articles
Dr. Chapman Describes the Vemurafenib Clinical TrialPublished: June 10th 2011 | Updated:
Dr. Chapman Describes Recent Melanoma AdvancesPublished: June 15th 2011 | Updated:
Dr. Chapman on Vemurafenib Combination TherapiesPublished: June 16th 2011 | Updated:
Dr. Chapman on BRAF/MEK Combination for MelanomaPublished: May 16th 2012 | Updated:
Dr. Chapman Describes the Side Effects of VemurafenibPublished: June 5th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5